Last updated: February 22, 2026
What is NDC 72603-0284?
NDC 72603-0284 is a specific drug identified in the National Drug Code (NDC) system. Based on available data, this NDC corresponds to Risdiplam (Evrysdi), marketed by Roche. Risdiplam is an oral medication approved for the treatment of spinal muscular atrophy (SMA).
Market Overview
Indication and Market Size
- SMA affects approximately 1 in 10,000 live births.
- The global SMA drug market is projected to reach $2.3 billion by 2027 (Grand View Research, 2022).
- Risdiplam entered the market in 2020 following FDA approval in August 2020.
Competitive Landscape
- Main competitors: Zolgensma (Novartis), Spinraza (Biogen).
- Spinraza dominated the early market but has seen competition from Risdiplam, which offers an oral administration alternative.
- Zolgensma is a one-time gene therapy, while Spinraza and Risdiplam are ongoing treatments.
Market Penetration
- Initial uptake among SMA patients was limited due to existing treatment preferences.
- By 2022, Risdiplam’s market share increased from 15% to 35%, overtaking Spinraza in certain segments (IQVIA, 2022).
Regulatory and Reimbursement Environment
- Floating approval in multiple markets: EMA (Europe), Japan, and other regions.
- Reimbursement coverage varies, typically favoring oral treatments for compliance ease.
Price Points and Cost
Current Market Price
- Estimated average wholesale price (AWP) for a monthly supply (dose-dependent): $16,000 to $18,000.
- Retail price per course (assuming a 12-month regimen): approximately $192,000 to $216,000.
Price Trends
- Initial launch prices were around $170,000 annually.
- Recent adjustments reflect competitive pressures and market expansion.
- U.S. list prices for Risdiplam are comparable to Spinraza but lower than Zolgensma on a per-year basis.
Pricing Compared to Competitors
| Drug |
Administration |
Annual Cost (USD) |
Market Penetration (2022) |
| Risdiplam (Evrysdi) |
Oral, once daily |
$192,000 - $216,000 |
35% |
| Spinraza |
Intrathecal injection |
~$750,000 first year, ~$350,000 subsequent years |
45% |
| Zolgensma |
Single infusion |
$2.1 million |
20% |
Market Projections
Growth Drivers
- Increasing diagnosis rates.
- Expanded approval in other countries.
- Higher health insurer reimbursement.
- Patient preference for oral versus injectable therapies.
Forecasts
- The SMA drug market is expected to grow compound annually at 7-9% through 2027.
- Risdiplam’s market share could reach 50% in pediatric SMA, driven by increasing approvals and formulary inclusion.
- Revenue projections for Risdiplam could exceed $600 million globally by 2025 (Global Data, 2023), assuming continued adoption and price stability.
Risks
- Pricing pressures from payers.
- Entry of biosimilars or generics.
- Regulatory developments in key markets.
Key Price and Market Dynamics Summary
- The drug’s current wholesale price around $170,000-$200,000 per year aligns with premium orphan drug pricing.
- Market competition and reimbursement policies are primary factors influencing price stability.
- Future price reductions are possible with increased competition, especially if biosimilars or generics enter the market.
Key Takeaways
- NDC 72603-0284, identified as Risdiplam (Evrysdi), holds a significant position in the SMA treatment market.
- Pricing remains high, reflecting the orphan drug market characteristics, with potential downward pressure from competitive factors.
- The global SMA treatment market continues to expand, with Risdiplam’s market share expected to grow due to oral administration advantages.
- Revenue forecasts suggest potential for premium pricing sustainment through increasing adoption and regulatory approvals.
- Market risks center around payer policies and competitive innovations.
FAQs
Q1: What factors influence the price of Risdiplam?
Pricing is influenced by manufacturing costs, reimbursement negotiations, competitive landscape, and orphan drug status premiums.
Q2: How does the market share of Risdiplam compare to its competitors?
As of 2022, Risdiplam captured 35% of the SMA drug market, overtaking Spinraza in some segments, but Zolgensma, with its high single-dose price, maintains a substantial share.
Q3: What is the potential for price reduction in the future?
Price reductions may occur as biosimilars or generics enter the market and as payer negotiations favor cost-containment strategies.
Q4: How does Risdiplam’s oral administration impact its marketability?
Oral administration offers convenience, potentially improves adherence, and enhances market penetration over injectable therapies.
Q5: What is the projected revenue for Risdiplam through 2027?
Revenues could exceed $600 million globally, contingent on continued adoption and approval pathways.
References
[1] Grand View Research. (2022). Spinal Muscular Atrophy Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Market Analysis Report for SMA Therapeutics.
[3] Global Data. (2023). SMA Drug Market Forecast.
